ESLA Q4 2024 Earnings — Estrella Immunopharma, Inc. Revenue & Financial Results | Market Cap Arena

ESLAEstrella Immunopharma, Inc.

$53M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$1M

Net Income

-$1M

EPS (Diluted)

$-0.03

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$896,066

Free Cash Flow

-$896,070

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$3M

Total Liabilities

$3M

Stockholders' Equity

$143,731

Cash & Equivalents

$916,916

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$1M	-$1M	-2.9%
Net Income	-$1M	-$1M	-2.9%